Market Intelligence, Clinical Progress, and High-Purity Reagents for Obesity, Metabolic Disorders, and Pancreatic Exocrine Insufficiency.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLPS (Colipase) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLPS Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified (UniProt P04118). |
View CLPS Products |
| Gene Delivery | CLPS Lentivirus / Promise-ORF Full-length ORF for stable cell lines. HEK293 expressed for authentic folding. |
View CLPS Products |
| Benchmark Ab | Anti-CLPS Recombinant Antibody Sequence-defined positive control for binding and capture assays. |
View CLPS Products |
| Validator | CLPS siRNA Set For knockdown verification in cellular models. |
View CLPS Products |
| Related Target A | PNLIP (Pancreatic Lipase) Direct enzymatic binding partner; essential for lipolytic activity and PPI studies. |
View PNLIP Products |
| Related Target B | PLRP2 (Pancreatic Lipase Related Protein 2) Paralog for counter-screening and selectivity assessment. |
View PLRP2 Products |
| Related Target C | CCK (Cholecystokinin) Metabolic signaling pathway modulation. |
View CCK Products |
| Related Target D | CEL (Carboxyl Ester Lipase) Synergistic pancreatic enzyme; relevant for comprehensive ERT development. |
View CEL Products |
Key Technical Specifications for Assay Development
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Lipase-Colipase Complex Formation Assay | Monomeric high-purity CLPS and PNLIP; accurate stoichiometric binding studies. |
| Cross-species Evaluation (Mouse Obesity Models) | Human, Mouse, and Cynomolgus orthologs available, Sequence Verified >95% purity. |
| Lack of Positive Controls | Recombinant Benchmark Antibodies included for reliable assay calibration. |
| False Positives in Pathway Analysis | Sequence-validated siRNA included for rigorous specificity checks. |
| Bile Salt-Dependent Protein Stability | High-purity CLPS with endotoxin control; compatible with detergent/bile salt testing. |
| Conformational Integrity Verification | Theoretical MW confirmed by mass spec; disulfide bond formation verified (reducing vs non-reducing). |
| Functional Lipase Activation Assay | Active cofactor format; native disulfide bond configuration for activity restoration. |
| Specificity vs. Related Cofactors/Lipases | Homolog panel (PLRP1/PLRP2) verified by mass spec for selectivity assays. |
Live CLPS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials on ClinicalTrials.gov
- ➤ Latest Research on PubMed (CLPS drug resistance & congenital deficiency)
- ➤ Recent Patent Filings on Google Patents
Global Clinical Landscape & Future Outlook
The race for metabolic and anti-obesity therapeutics is experiencing a renaissance. Historically, generic pancreatic lipase inhibitors (e.g., Orlistat) dominated the gastrointestinal weight-loss market but caused significant steatorrhea. The targeted disruption of the CLPS–PNLIP interaction offers a next-generation approach: by specifically modulating colipase, developers aim to achieve controlled triglyceride hydrolysis inhibition while minimizing side effects. As the GLP-1 receptor agonist market expands, CLPS modulators are being explored as oral combination agents to prevent weight regain.
Simultaneously, the enzyme replacement therapy (ERT) landscape for rare congenital colipase deficiency and severe pancreatic exocrine insufficiency (PEI) is evolving from crude animal extracts to recombinant human CLPS. Key R&D focuses include:
- Stable Formulation Development: Enhancing gastric stability to prevent degradation before reaching the duodenum.
- Cofactor Optimization: Engineering variants with enhanced PNLIP binding affinity.
- Combination ERT: Co-formulation with lipases (PNLIP) and amylases for comprehensive digestive support.
- Diagnostic Assays: Improved newborn screening and pancreatic function tests require high-quality recombinant CLPS standards.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Metabolic Biotechs | Obesity, Hyperlipidemia, Metabolic Syndrome | Complex Disruption Assay (high-purity CLPS/PNLIP proteins) |
| Peptide Inhibitor | Emerging Innovators | Metabolic Syndrome | Binding Affinity SPR (endotoxin-controlled reagents) |
| Enzyme Replacement (ERT) | Orphan Biotechs, GI Specialists | Congenital Colipase Deficiency, Severe PEI | Functional Activation Assay (native-folded CLPS) |
| Adjunctive ERT | Cystic Fibrosis Therapy Developers | CF-related PEI | Stability Testing (gastric-resistant variants) |
| Diagnostic Assays | Clinical Diagnostics Companies | Exocrine Pancreatic Function Testing | Immunoassay Standards (calibrated reference proteins) |
| Protein Engineering | Rare Disease Biotechs | Metabolic Malabsorption Disorders | Mutant vs WT Comparison (disease-variant proteins) |
Key Genetic Variants of CLPS
The following naturally occurring variants are catalogued in dbSNP and have been linked to altered colipase function or disease risk:
- rs2766597 (UniProt VAR_053040): missense variant in the colipase coding region.
- rs41270082 (UniProt VAR_047105): another coding variant with potential structural impact.
These variants are critical for studying population-specific differences in lipid digestion and for developing personalized therapeutic strategies. TarMart offers recombinant CLPS proteins with these specific mutations for functional validation.
Assay Strategy Recommendations for Best-in-Class Drug Development
1. Binding Affinity & Kinetics (PPI Disruption)
- Need: nM-level binding to CLPS or precise blockade of the CLPS–PNLIP interface.
- Assay: SPR or BLI using high-purity monomeric CLPS and PNLIP (no interfering tags).
2. Specificity & Safety
- Need: No cross-reactivity with non-CLPS-dependent lipases (e.g., hepatic lipase).
- Assay: Counter-screening panel including PLRP1, PLRP2, and CEL.
3. Physiological Functionality
- Need: Activity under intestinal pH (mildly alkaline) and high bile salt conditions.
- Assay: Simulated intestinal fluid (SIF) triglyceride hydrolysis kinetic assay.
4. Species Cross-Reactivity
- Need: Preclinical safety evaluation requires human/mouse/cynomolgus ortholog performance data.
- TarMart Supply: Strictly matched ortholog panels with >90% sequence identity.
5. High-Concentration Stability
- Need: Formulation feasibility; aggregation propensity at >10 mg/mL.
- Assay: Accelerated stability (40°C/75% RH) with SEC-HPLC.
TarMart provides all necessary reagents: high-purity CLPS (human/mouse/cyno), PNLIP, benchmark antibodies, and siRNA sets, enabling seamless assay development from screening to IND submission.